Erythropoietin: From Regulator of Erythropoiesis to Multisystem Protective Factor

This article focuses on the molecular characteristics and biological functions of erythropoietin (EPO), systematically elaborating its central role as a glycoprotein hormone secreted by the kidneys in regulating erythropoiesis, analyzing the molecular mechanisms of its regulation by hypoxia-inducible factors, and exploring its multiple pharmacological potentials in tissue protection.

Recent Advances
Product Information

Recent Advances

Erythropoietin: From Erythropoiesis Regulator to Multi-System Protective Factor

Overview
This article systematically elaborates on the molecular characteristics and biological functions of erythropoietin (EPO), highlighting its central role as a glycoprotein hormone secreted by the kidneys in regulating erythropoiesis. It analyzes the molecular mechanisms of its regulation by hypoxia-inducible factors and explores its multifaceted pharmacological potential in tissue protection.

I. Molecular Structure and Biosynthetic Origins of EPO

Erythropoietin (EPO) is an endogenous glycoprotein hormone composed of 165 amino acid residues, with a molecular weight of approximately 34 kDa. Glycosylation modifications account for about 30% of its total mass, conferring excellent structural stability and biological activity. The EPO gene is located on the q21-22 region of human chromosome 7, consisting of five exons and four introns. The encoded protein structure features four antiparallel α-helices, providing a precise conformational basis for receptor binding.

In terms of biosynthesis, EPO production exhibits distinct developmental stage transitions. During fetal development, the liver is the primary site of EPO synthesis. After birth, the kidneys gradually become the main source, with approximately 80% of circulating EPO produced by peritubular interstitial cells in the renal cortex, while the remaining 20% originates from the liver and other tissues. Notably, recent studies have revealed that osteoblasts can also produce and secrete EPO upon activation of hypoxia-inducible factor 2α (HIF-2), suggesting bone tissue as an additional source of EPO involved in hematopoietic regulation.

II. Molecular Mechanisms of EPO in Erythropoiesis Regulation

EPO production is precisely regulated by the body's oxygen supply-demand balance. Under normoxic conditions, the oxygen-dependent degradation domain of HIF-1α is hydroxylated by prolyl hydroxylases, subsequently recognized by the VHL tumor suppressor protein and targeted for ubiquitin-proteasome pathway degradation, thereby inhibiting EPO gene transcription. During tissue hypoxia—such as in anemia or high-altitude exposure—HIF-1α/2α stabilizes and translocates to the nucleus, forming heterodimers with HIF-1β to initiate transcription of the EPO gene and other hypoxia-responsive genes.

EPO exerts its biological effects by binding to its cell surface receptor (EPOR). EPOR belongs to the type I cytokine receptor superfamily and is highly expressed on erythroid progenitor cells, existing as preformed homodimers. Upon EPO binding, EPOR undergoes conformational changes, activating the associated JAK2 tyrosine kinase, which phosphorylates tyrosine residues in the receptor's intracellular domain, initiating downstream signaling pathways such as STAT5, PI3K/AKT, and Ras/MAPK. The coordinated activation of these pathways promotes erythroid progenitor survival by upregulating anti-apoptotic proteins like Bcl-xL while driving their proliferation and terminal differentiation into erythrocytes.

III. Multifaceted Tissue-Protective Functions of EPO

The physiological functions of EPO extend far beyond hematopoietic regulation. Studies have confirmed that EPO receptors are expressed in the nervous system, heart, kidneys, vascular endothelium, and various non-hematopoietic tissues, indicating EPO's broad pleiotropic effects. In the central nervous system, EPO exerts neurotrophic and neuroprotective effects through paracrine or autocrine mechanisms, mitigating hypoxic-ischemic neuronal damage. In the cardiovascular system, EPO protects cardiomyocytes from ischemia-reperfusion injury. Additionally, EPO has been reported to possess potential pharmacological effects, such as reducing inflammatory responses and maintaining intestinal barrier function. These multi-system protective effects suggest that EPO may serve as a universal defense factor under hypoxic stress conditions.

IV. Conclusion

As a molecular bridge connecting tissue oxygenation status with hematopoietic responses, EPO plays an irreplaceable role in maintaining the body's oxygen supply-demand balance. Its production is precisely regulated by the HIF pathway, promoting erythropoiesis through the JAK2/STAT5 signaling axis. Simultaneously, EPO's effects in the nervous, cardiovascular, and other systems continue to be revealed, expanding its application prospects as a pleiotropic protective factor. Recombinant human EPO protein, as a vital tool for basic research and drug development, will continue to provide critical support for in-depth exploration of EPO signaling networks and their translational applications.

In EPO-related basic research, signaling pathway analysis, and cellular function experiments, high-quality recombinant human EPO protein is an essential experimental tool. To meet this research demand, UniLove offers EPO Protein, Human, suitable for studies on the proliferation and differentiation of human erythroid progenitor cells, mechanistic exploration of the JAK2/STAT5 signaling pathway, and in vitro evaluation of EPO-EPOR binding activity.

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next